Basic Information
| LncRNA/CircRNA Name | HCG11 |
| Synonyms | NA |
| Region | GRCh38_6:26521709-26527404 |
| Ensemble | ENSG00000228223 |
| Refseq | NR_026790 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | Human prostate normal cell lines RWPE1 and human prostate cancer cell lines LNCaP, PC-3 and C4-2B as well as HEK293T cell lines, prostate cancer tissues (non-metastasis and metastasis tissues) and adjacent normal tissues |
| Expression Pattern | down-regulated |
| Function Description | overexpression of HCG11 inhibited cell proliferation, invasion and migration, whereas induced cell apoptosis by regulating miR-543 expression in vitro and in vivo. More than that, LncRNA HCG11 inhibited PI3K/AKT signaling pathway to suppress PCa progression. Our data showed the overexpression of HGC11 inhibited PI3K/AKT signaling pathway by down-regulating miR-543 expression, resulting in the suppression of cell growth in PCa. |
| Pubmed ID | 31228307 |
| Year | 2019 |
| Title | LncRNA HCG11 regulates cell progression by targeting miR-543 through regulating AKT/mTOR pathway in prostate cancer |
External Links
| Links for HCG11 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |